RT Journal Article
SR Electronic
T1 Efficacy of Adoptive Immune-cell Therapy in Patients with Advanced Gastric Cancer: A Retrospective Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3947
OP 3954
VO 37
IS 7
A1 RISHU TAKIMOTO
A1 TAKASHI KAMIGAKI
A1 SACHIKO OKADA
A1 ERIKO MATSUDA
A1 HIROSHI IBE
A1 ERI OGUMA
A1 KEIKO NAITOH
A1 KAORI MAKITA
A1 SHIGENORI GOTO
YR 2017
UL http://ar.iiarjournals.org/content/37/7/3947.abstract
AB Background: Conventional therapy for advanced gastric cancer (GC) has limited survival benefits. In this retrospective study, we aimed to investigate the efficacy of immune-cell therapy, using in vitro-activated T-lymphocytes with and without dendritic cells (DCs), in combination with standard therapies in terms of the survival of patients with advanced GC. Patients and Methods: A total of 242 patients who were diagnosed as having stage-IV GC were enrolled in this study to receive immune-cell therapy with or without standard therapies, such as chemotherapy, surgery, or radiation therapy. Overall survival was analyzed by the Kaplan–Meier with log-rank test and Cox regression methods. Results: Immune-cell therapy increased median survival time (21.5 months) in patients with advanced GC. The patients who underwent surgery with or without chemotherapy as a prior treatment showed better prognosis than those who received other therapies (p<0.001). Patients who showed stable disease or a partial response to immune-cell therapy had a better prognosis than those with progressive disease (p<0.001). Multivariate analysis revealed that performance status, the type of immune-cell therapy, and prior treatment were independent prognostic factors for patients with GC. No serious adverse event was reported in immune-cell therapy. Conclusion: Immune-cell therapy might extend the survival of patients with advanced GC.